<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715101</url>
  </required_header>
  <id_info>
    <org_study_id>Rosuvastatin_Elderly</org_study_id>
    <nct_id>NCT03715101</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate PK, PD, and PG of Rosuvastatin in the Elderly</brief_title>
  <official_title>A Clinical Study to Evaluate Pharmacokinetic, Pharmacodynamic, and Pharmacogenomic Characteristics of Rosuvastatin in the Elderly After Multiple Administration of Rosuvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate pharmacokinetic, pharmacodynamic, and pharmacogenomic
      characteristics of Rosuvastatin in the elderly after multiple administration of Rosuvastatin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (Tmax; time to reach maximum plasma concentration) of rosuvastatin</measure>
    <time_frame>Day 21 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour, 12 hour, 24 hour</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (Cmax; peak plasma concentration) of rosuvastatin</measure>
    <time_frame>Day 21 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour, 12 hour, 24 hour</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (AUC; area under the concentration-time curve) of rosuvastatin</measure>
    <time_frame>Day 21 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour, 12 hour, 24 hour</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lipid panel (low-density lipoprotein cholesterol in mg/dL)</measure>
    <time_frame>Day 1 0 hour, Day 11 0 hour, Day 22 0 hour</time_frame>
    <description>Pharmacodynamic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid panel (high-density lipoprotein cholesterol in mg/dL)</measure>
    <time_frame>Day 1 0 hour, Day 11 0 hour, Day 22 0 hour</time_frame>
    <description>Pharmacodynamic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid panel (Triglyceride in mg/dL)</measure>
    <time_frame>Day 1 0 hour, Day 11 0 hour, Day 22 0 hour</time_frame>
    <description>Pharmacodynamic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid panel (Total cholesterol in units of mg/dL)</measure>
    <time_frame>Day 1 0 hour, Day 11 0 hour, Day 22 0 hour</time_frame>
    <description>Pharmacodynamic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid metabolites</measure>
    <time_frame>Day -1 0 hour, Day 21 0 hour</time_frame>
    <description>Metabolites evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Elderly</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin 20 mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg daily for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Open-label, one-sequence, multiple administration</description>
    <arm_group_label>Rosuvastatin 20 mg PO</arm_group_label>
    <other_name>Rosuvastatin 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Subjects aged 65 - 85 years

          -  A body mass index (BMI) in the range of 18.5 kg/m2 - 27.0 kg/m2.

          -  Good health based on complete medical history, physical examinations, vital signs,
             electrocardiography (ECG), and clinical laboratory evaluations.

        Exclusion Criteria:

          -  Subjects who have clinically significant disease of cardiovascular, respiratory,
             renal, endocrinological, hematological, gastrointestinal, neurological(central nervous
             system), psychiatric disorders or malignant tumor

          -  Subject judged not eligible for study participation by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Yong Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Korea Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae Yong Chung, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

